ALNYLAM PHARMACEUTICALS, INC. Operating Cash Flow
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Operating Cash Flow of $397.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $163.56M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $351.03M, a 703.14% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was $127.81M, a 2.94% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$118.31M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $524.08M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$8.31M, a 107.98% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was $104.16M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$541.27M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $397.23M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $163.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $514.59M derived: sum of 2 quarters · filed 2026-02-12 | $642.39M derived: sum of 3 quarters · filed 2026-07-30 | $524.08M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $351.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $478.84M derived: sum of 2 quarters · filed 2026-07-30 | $360.52M 10-Q · filed 2025-10-30 | $265.86M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $127.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $9.49M 10-Q · filed 2026-07-30 | $35.42M 10-Q · filed 2025-07-31 | -$85.17M derived: sum of 3 quarters · filed 2026-07-30 | -$41.46M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$118.31M 10-Q · filed 2025-05-01 | -$212.98M derived: sum of 2 quarters · filed 2026-02-12 | -$169.27M derived: sum of 3 quarters · filed 2026-02-12 | -$45.11M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | -$94.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$50.95M derived: sum of 2 quarters · filed 2026-02-12 | $73.20M derived: sum of 3 quarters · filed 2026-02-12 | -$8.31M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $43.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $167.87M derived: sum of 2 quarters · filed 2025-10-30 | $86.35M 10-Q · filed 2025-10-30 | $56.55M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $124.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $42.64M 10-Q · filed 2025-07-31 | $12.85M derived: sum of 3 quarters · filed 2026-02-12 | $372.26M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | -$81.52M 10-Q · filed 2025-05-01 | -$111.31M derived: sum of 2 quarters · filed 2026-02-12 | $248.10M derived: sum of 3 quarters · filed 2026-02-12 | $189.12M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | -$29.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $329.62M derived: sum of 2 quarters · filed 2026-02-12 | $270.63M derived: sum of 3 quarters · filed 2026-02-12 | $104.16M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $359.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $300.43M derived: sum of 2 quarters · filed 2024-10-31 | $133.95M 10-Q · filed 2024-10-31 | $1.97M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | -$58.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$225.46M 10-Q · filed 2024-08-01 | -$357.44M derived: sum of 3 quarters · filed 2025-02-13 | -$472.72M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | -$166.47M 10-Q · filed 2024-05-02 | -$298.45M derived: sum of 2 quarters · filed 2025-02-13 | -$413.74M derived: sum of 3 quarters · filed 2025-02-13 | -$536.56M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | -$131.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$247.26M derived: sum of 2 quarters · filed 2025-02-13 | -$370.08M derived: sum of 3 quarters · filed 2025-02-13 | -$541.27M 10-K · filed 2025-02-13 | |
| 2022-09-30 | -$115.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$238.10M derived: sum of 2 quarters · filed 2023-11-02 | -$409.30M 10-Q · filed 2023-11-02 | -$559.44M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | -$122.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$294.01M 10-Q · filed 2023-08-03 | -$444.15M derived: sum of 3 quarters · filed 2024-02-15 | -$578.19M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | -$171.19M 10-Q · filed 2023-05-04 | -$321.33M derived: sum of 2 quarters · filed 2024-02-15 | -$455.37M derived: sum of 3 quarters · filed 2024-02-15 | -$577.23M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | -$150.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$284.18M derived: sum of 2 quarters · filed 2024-02-15 | -$406.03M derived: sum of 3 quarters · filed 2024-02-15 | -$641.69M 10-K · filed 2024-02-15 | |
| 2021-09-30 | -$134.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$255.89M derived: sum of 2 quarters · filed 2022-10-27 | -$491.55M 10-Q · filed 2022-10-27 | -$614.70M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$121.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | -$357.52M 10-Q · filed 2022-07-28 | -$480.66M derived: sum of 3 quarters · filed 2023-02-23 | -$590.99M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$235.66M 10-Q · filed 2022-04-28 | -$358.80M derived: sum of 2 quarters · filed 2023-02-23 | -$469.13M derived: sum of 3 quarters · filed 2023-02-23 | -$604.46M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | -$123.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$233.47M derived: sum of 2 quarters · filed 2023-02-23 | -$368.80M derived: sum of 3 quarters · filed 2023-02-23 | -$614.96M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$110.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$245.66M derived: sum of 2 quarters · filed 2021-10-28 | -$491.82M 10-Q · filed 2021-10-28 | -$687.80M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-06-30 | -$135.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$381.49M 10-Q · filed 2021-08-03 | -$577.47M derived: sum of 3 quarters · filed 2022-02-10 | -$760.10M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-03-31 | -$246.16M 10-Q · filed 2021-04-29 | -$442.14M derived: sum of 2 quarters · filed 2022-02-10 | -$624.77M derived: sum of 3 quarters · filed 2022-02-10 | -$336.08M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2019-12-31 | -$195.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$378.61M derived: sum of 2 quarters · filed 2022-02-10 | -$89.92M derived: sum of 3 quarters · filed 2022-02-10 | -$278.43M 10-K · filed 2022-02-10 | |
| 2019-09-30 | -$182.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $106.06M derived: sum of 2 quarters · filed 2020-11-05 | -$82.45M 10-Q · filed 2020-11-05 | -$232.90M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $288.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $100.19M 10-Q · filed 2020-08-06 | -$50.27M derived: sum of 3 quarters · filed 2021-02-11 | -$204.08M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | -$188.51M 10-Q · filed 2020-05-06 | -$338.97M derived: sum of 2 quarters · filed 2021-02-11 | -$492.77M derived: sum of 3 quarters · filed 2021-02-11 | -$595.46M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | -$150.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$304.26M derived: sum of 2 quarters · filed 2021-02-11 | -$406.95M derived: sum of 3 quarters · filed 2021-02-11 | -$562.62M 10-K · filed 2021-02-11 | |
| 2018-09-30 | -$153.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$256.50M derived: sum of 2 quarters · filed 2019-10-31 | -$412.16M 10-Q · filed 2019-10-31 | -$515.20M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | -$102.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$258.35M 10-Q · filed 2019-08-06 | -$361.39M derived: sum of 3 quarters · filed 2020-02-13 | -$459.76M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | -$155.66M 10-Q · filed 2019-05-02 | -$258.71M derived: sum of 2 quarters · filed 2020-02-13 | -$357.07M derived: sum of 3 quarters · filed 2020-02-13 | ||
| 2017-12-31 | -$103.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$201.41M derived: sum of 2 quarters · filed 2020-02-13 | -$382.79M 10-K · filed 2020-02-13 | ||
| 2017-09-30 | -$98.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$279.74M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | -$181.38M 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | -$307.70M 10-K · filed 2019-02-14 | ||||
| 2013-12-31 | -$22.37M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$44.08M derived: sum of 2 quarters · filed 2014-02-20 | -$67.69M derived: sum of 3 quarters · filed 2014-02-20 | -$68.66M 10-K · filed 2014-02-20 | |
| 2013-09-30 | -$21.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$45.32M derived: sum of 2 quarters · filed 2013-11-07 | -$46.29M 10-Q · filed 2013-11-07 | -$115.20M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2013-06-30 | -$23.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$24.57M 10-Q · filed 2013-08-09 | -$93.48M derived: sum of 3 quarters · filed 2014-02-20 | -$88.27M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2013-03-31 | -$971.00K 10-Q · filed 2013-05-07 | -$69.88M derived: sum of 2 quarters · filed 2014-02-20 | -$64.67M derived: sum of 3 quarters · filed 2014-02-20 | -$86.36M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2012-12-31 | -$68.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$63.70M derived: sum of 2 quarters · filed 2014-02-20 | -$85.39M derived: sum of 3 quarters · filed 2014-02-20 | -$115.61M 10-K · filed 2014-02-20 | |
| 2012-09-30 | $5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$16.48M derived: sum of 2 quarters · filed 2013-11-07 | -$46.70M 10-Q · filed 2013-11-07 | -$71.86M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2012-06-30 | -$21.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$51.91M 10-Q · filed 2013-08-09 | -$77.07M derived: sum of 3 quarters · filed 2014-02-20 | -$106.09M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2012-03-31 | -$30.21M 10-Q · filed 2013-05-07 | -$55.37M derived: sum of 2 quarters · filed 2014-02-20 | -$84.40M derived: sum of 3 quarters · filed 2014-02-20 | -$110.98M derived: sum of 4 quarters · filed 2014-02-20 | |
| 2011-12-31 | -$25.16M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | -$54.18M derived: sum of 2 quarters · filed 2014-02-20 | -$80.76M derived: sum of 3 quarters · filed 2014-02-20 | -$87.07M 10-K · filed 2014-02-20 | |
| 2011-09-30 | -$29.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$55.60M derived: sum of 2 quarters · filed 2012-11-05 | -$61.91M 10-Q · filed 2012-11-05 | -$82.30M derived: sum of 4 quarters · filed 2013-02-19 | |
| 2011-06-30 | -$26.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$32.88M 10-Q · filed 2012-08-08 | -$53.27M derived: sum of 3 quarters · filed 2013-02-19 | -$77.31M derived: sum of 4 quarters · filed 2013-02-19 | |
| 2011-03-31 | -$6.30M 10-Q · filed 2012-05-03 | -$26.69M derived: sum of 2 quarters · filed 2013-02-19 | -$50.73M derived: sum of 3 quarters · filed 2013-02-19 | -$75.05M derived: sum of 4 quarters · filed 2013-02-19 | |
| 2010-12-31 | -$20.39M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | -$44.43M derived: sum of 2 quarters · filed 2013-02-19 | -$68.74M derived: sum of 3 quarters · filed 2013-02-19 | -$84.34M 10-K · filed 2013-02-19 | |
| 2010-09-30 | -$24.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$48.35M derived: sum of 2 quarters · filed 2011-11-03 | -$63.95M 10-Q · filed 2011-11-03 | -$80.82M derived: sum of 4 quarters · filed 2012-02-13 | |
| 2010-06-30 | -$24.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | -$39.91M 10-Q · filed 2011-08-03 | -$56.78M derived: sum of 3 quarters · filed 2012-02-13 | -$77.37M derived: sum of 4 quarters · filed 2012-02-13 | |
| 2010-03-31 | -$15.60M 10-Q · filed 2011-05-05 | -$32.47M derived: sum of 2 quarters · filed 2012-02-13 | -$53.06M derived: sum of 3 quarters · filed 2012-02-13 | ||
| 2009-12-31 | -$16.87M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | -$37.46M derived: sum of 2 quarters · filed 2012-02-13 | -$72.14M 10-K · filed 2012-02-13 | ||
| 2009-09-30 | -$20.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | -$55.28M 10-Q · filed 2010-11-04 | |||
| 2009-06-30 | -$34.69M 10-Q · filed 2010-08-05 | ||||
| 2008-12-31 | $65.49M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |